Search

Your search keyword '"Liapis, Christos D."' showing total 228 results
Start Over Author "Liapis, Christos D." Search Limiters Peer Reviewed
228 results on '"Liapis, Christos D."'

1. Recent advances and controversial issues in the optimal management of asymptomatic carotid stenosis

Author

Paraskevas, Kosmas I., Brown, Martin M., Lal, Brajesh K., Myrcha, Piotr, Lyden, Sean P., Schneider, Peter A., Poredos, Pavel, Mikhailidis, Dimitri P., Secemsky, Eric A., Musialek, Piotr, Mansilha, Armando, Parikh, Sahil A., Silvestrini, Mauro, Lavie, Carl J., Dardik, Alan, Blecha, Matthew, Liapis, Christos D., Zeebregts, Clark J., Nederkoorn, Paul J., Poredos, Peter, Gurevich, Victor, Jawien, Arkadiusz, Lanza, Gaetano, Gray, William A., Gupta, Ajay, Svetlikov, Alexei V., Fernandes e Fernandes, Jose, Nicolaides, Andrew N., White, Christopher J., Meschia, James F., Cronenwett, Jack L., Schermerhorn, Marc L., and AbuRahma, Ali F.

Published
2024
Full Text
View/download PDF

2. An international, multispecialty, expert-based Delphi Consensus document on controversial issues in the management of patients with asymptomatic and symptomatic carotid stenosis

Author

Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Ringleb, Peter Arthur, Brown, Martin M., Dardik, Alan, Poredos, Pavel, Gray, William A., Nicolaides, Andrew N., Lal, Brajesh K., Mansilha, Armando, Antignani, Pier Luigi, de Borst, Gert J., Cambria, Richard P., Loftus, Ian M., Lavie, Carl J., Blinc, Ales, Lyden, Sean P., Matsumura, Jon S., Jezovnik, Mateja K., Bacharach, J. Michael, Meschia, James F., Clair, Daniel G., Zeebregts, Clark J., Lanza, Gaetano, Capoccia, Laura, Spinelli, Francesco, Liapis, Christos D., Jawien, Arkadiusz, Parikh, Sahil A., Svetlikov, Alexei, Menyhei, Gabor, Davies, Alun H., Musialek, Piotr, Roubin, Gary, Stilo, Francesco, Sultan, Sherif, Proczka, Robert M., Faggioli, Gianluca, Geroulakos, George, Fernandes e Fernandes, Jose, Ricco, Jean-Baptiste, Saba, Luca, Secemsky, Eric A., Pini, Rodolfo, Myrcha, Piotr, Rundek, Tatjana, Martinelli, Ombretta, Kakkos, Stavros K., Sachar, Ravish, Goudot, Guillaume, Schlachetzki, Felix, Lavenson, George S., Jr., Ricci, Stefano, Topakian, Raffi, Millon, Antoine, Di Lazzaro, Vincenzo, Silvestrini, Mauro, Chaturvedi, Seemant, Eckstein, Hans-Henning, Gloviczki, Peter, and White, Christopher J.

Published
2024
Full Text
View/download PDF

3. Why do guidelines recommend screening for abdominal aortic aneurysms, but not for asymptomatic carotid stenosis? A plea for a randomized controlled trial

Author

Paraskevas, Kosmas I., Spence, J. David, Mikhailidis, Dimitri P., Antignani, Pier Luigi, Gloviczki, Peter, Eckstein, Hans-Henning, Spinelli, Francesco, Stilo, Francesco, Saba, Luca, Poredos, Pavel, Dardik, Alan, Liapis, Christos D., Mansilha, Armando, Faggioli, Gianluca, Pini, Rodolfo, Jezovnik, Mateja K., Sultan, Sherif, Musiałek, Piotr, Goudot, Guillaume, Lavenson, George S., Jr, Jawien, Arkadiusz, Blinc, Aleš, Myrcha, Piotr, Fernandes e Fernandes, Jose, Geroulakos, George, Kakkos, Stavros K., Knoflach, Michael, Proczka, Robert M., Capoccia, Laura, Rundek, Tatjana, Svetlikov, Alexei S., Silvestrini, Mauro, Ricco, Jean-Baptiste, Davies, Alun H., Di Lazzaro, Vincenzo, Suri, Jasjit S., Lanza, Gaetano, Fraedrich, Gustav, Zeebregts, Clark J., and Nicolaides, Andrew N.

Published
2023
Full Text
View/download PDF

4. Optimal Management of Asymptomatic Carotid Stenosis in 2021: The Jury is Still Out. An International, Multispecialty, Expert Review and Position Statement

Author

Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Antignani, Pier Luigi, Baradaran, Hediyeh, Bokkers, Reinoud P.H., Cambria, Richard P., Dardik, Alan, Davies, Alun H., Eckstein, Hans-Henning, Faggioli, Gianluca, e Fernandes, Jose Fernandes, Fraedrich, Gustav, Geroulakos, George, Gloviczki, Peter, Golledge, Jonathan, Gupta, Ajay, Jezovnik, Mateja K., Kakkos, Stavros K., Katsiki, Niki, Knoflach, Michael, Kooi, M. Eline, Lanza, Gaetano, Liapis, Christos D., Loftus, Ian M., Mansilha, Armando, Millon, Antoine, Nicolaides, Andrew N., Pini, Rodolfo, Poredos, Pavel, Ricco, Jean-Baptiste, Riles, Thomas S., Ringleb, Peter Arthur, Rundek, Tatjana, Saba, Luca, Schlachetzki, Felix, Silvestrini, Mauro, Spinelli, Francesco, Stilo, Francesco, Sultan, Sherif, Suri, Jasjit S., Zeebregts, Clark J., and Chaturvedi, Seemant

Published
2022
Full Text
View/download PDF

5. Contemporary Outcomes After Partial Resection of Infected Aortic Grafts

Author

Janko, Matthew, Hubbard, Grant, Woo, Karen, Kashyap, Vikram S., Mitchell, Megan, Murugesan, Arun, Chen, Lin, Gardner, Rachel, Baril, Donald, Hacker, Robert I., Szeberin, Zoltan, ElSayed, Ramsey, Magee, Gregory A., Motta, Fernando, Zhou, Wei, Lemmon, Gary, Coleman, Dawn, Behrendt, Christian-Alexander, Aziz, Faisal, Black, James H., Tran, Kimberly, Dao, Allen, Shutze, William, Garrett, H. Edward, De Caridi, Giovanni, Patel, Rhusheet, Liapis, Christos D., Geroulakos, George, Kakisis, John, Moulakakis, Konstantinos, Kakkos, Starvos K., Obara, Hideaki, Wang, Grace, Stoecker, Jordan, Rhéaume, Pascal, Davila, Victor, Ravin, Reid, DeMartino, Randall, Milner, Ross, Shalhub, Sherene, Jim, Jeffrey, Lee, Jason, Dubuis, Celine, Ricco, Jean-Baptiste, Coselli, Joseph, Lemaire, Scott, Fatima, Javairiah, Sanford, Jennifer, Yoshida, Winston, Schermerhorn, Marc L, Menard, Matthew, Belkin, Michael, Blackwood, Stuart, Conrad, Mark, Wang, Linda, Crofts, Sara, Nixon, Thomas, Wu, Timothy, Chiesa, Roberto, Bose, Saideep, Turner, Jason, Moore, Ryan, Smith, Justin, Irshad, Ali, Hsu, Jeffrey, Czerny, Martin, Cullen, Jonathan, Kahlberg, Andrea, Setacci, Carlo, Joh, Jin Hyun, Senneville, Eric, Garrido, Pedro, Sarac, Timur P., Rizzo, Anthony, Go, Michael R., Bjorck, Martin, Gavali, Hamid, Wanhainen, Anders, D'Oria, Mario, Lepidi, Sandro, Mastrorilli, Davide, Veraldi, Gianfranco, Piazza, Michele, Squizzato, Francesco, Beck, Adam, St. John, Rebecca, Wishy, Andrew, Humphries, Misty, Shah, Samir K., Back, Martin, Chung, Jayer, Lawrence, Peter F, Bath, Jonathan, and Smeds, Matthew R.

Published
2021
Full Text
View/download PDF

6. In situ bypass and extra-anatomic bypass procedures result in similar survival in patients with secondary aortoenteric fistulas

Author

Janko, Matthew R., Woo, Karen, Hacker, Robert I., Baril, Donald, Bath, Jonathan, Smeds, Matthew R., Kashyap, Vikram S., Szeberin, Zoltan, Magee, Gregory A., Elsayed, Ramsey, Wishy, Andrew, St. John, Rebecca, Beck, Adam, Farber, Mark, Motta, Fernando, Zhou, Wei, Lemmon, Gary, Coleman, Dawn, Behrendt, Christian-Alexander, Aziz, Faisal, Black, James, Shutze, William, Garrett, H. Edward, Jr., De Caridi, Giovanni, Liapis, Christos D., Geroulakos, George, Kakisis, John, Moulakakis, Konstantinos, Kakkos, Stavros K., Obara, Hideaki, Wang, Grace, Rhéaume, Pascal, Davila, Victor, Ravin, Reid, DeMartino, Randall, Milner, Ross, Shalhub, Sherene, Jim, Jeffrey, Lee, Jason, Dubuis, Celine, Ricco, Jean-Baptiste, Coselli, Joseph, Lemaire, Scott, Fatima, Javairiah, Sanford, Jennifer, Yoshida, Winston, Schermerhorn, Marc L., Menard, Matthew, Belkin, Michael, Blackwood, Stuart, Conrad, Mark, Wang, Linda, Crofts, Sara, Nixon, Thomas, Wu, Timothy, Chiesa, Roberto, Bose, Saideep, Turner, Jason, Moore, Ryan, Smith, Justin, Ciocca, Rocco, Hsu, Jeffrey, Czerny, Martin, Cullen, Jonathan, Kahlberg, Andrea, Setacci, Carlo, Joh, Jin Hyun, Senneville, Eric, Garrido, Pedro, Sarac, Timur P., Rizzo, Anthony, Go, Michael R., Bjorck, Martin, Gavali, Hamid, Wanhainen, Anders, Lawrence, Peter F., and Chung, Jayer

Published
2021
Full Text
View/download PDF

7. Why selective screening for asymptomatic carotid stenosis is currently appropriate: a special report.

Author

Paraskevas, Kosmas I., Dardik, Alan, Schermerhorn, Marc L., Liapis, Christos D., Mansilha, Armando, Lal, Brajesh K., Gray, William A., Brown, Martin M., Myrcha, Piotr, Lavie, Carl J., Zeebregts, Clark J., Secemsky, Eric A., Saba, Luca, Blecha, Matthew, Gurevich, Victor, Silvestrini, Mauro, Blinc, Ales, Svetlikov, Alexei, Fernandes e Fernandes, Jose, and Schneider, Peter A.

Subjects
CAROTID artery stenosis, MEDICAL screening, MYOCARDIAL infarction, STROKE, THERAPEUTICS
Abstract

Two of the main reasons recent guidelines do not recommend routine population-wide screening programs for asymptomatic carotid artery stenosis (AsxCS) is that screening could lead to an increase of carotid revascularization procedures and that such mass screening programs may not be cost-effective. Nevertheless, selective screening for AsxCS could have several benefits. This article presents the rationale for such a program. The benefits of selective screening for AsxCS include early recognition of AsxCS allowing timely initiation of preventive measures to reduce future myocardial infarction (MI), stroke, cardiac death and cardiovascular (CV) event rates. Mass screening programs for AsxCS are neither clinically effective nor cost-effective. Nevertheless, targeted screening of populations at high risk for AsxCS provides an opportunity to identify these individuals earlier rather than later and to initiate a number of lifestyle measures, risk factor modifications, and intensive medical therapy in order to prevent future strokes and CV events. For patients at 'higher risk of stroke' on best medical treatment, a prophylactic carotid intervention may be considered. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Rupture After Endovascular Abdominal Aortic Aneurysm Repair: A Multicenter Study

Author

Antonopoulos, Constantine N., Kakisis, John D., Giannakopoulos, Triantafillos G., Andrikopoulos, Vasilios, Antoniadis, Pavlos, Bessias, Nikolaos, Dervisis, Konstantinos, Georgopoulos, Sotirios, Giannoukas, Athanasios, Kaperonis, Elias, Kiskinis, Dimitrios, Klonaris, Christos, Machairas, Anastasios, Papavassiliou, Vasilios, Saleptsis, Vasilios, Saratzis, Nikolaos, Seretis, Konstantinos, Tampakis, Charalambos, and Liapis, Christos D.

Published
2014
Full Text
View/download PDF

36. Optimal periprocedural antithrombotic treatment in carotid interventions: An international, multispecialty, expert review and position statement.

Author

Paraskevas, Kosmas I., Gloviczki, Peter, Mikhailidis, Dimitri P., Antignani, Pier Luigi, Dardik, Alan, Eckstein, Hans-Henning, Faggioli, Gianluca, Fernandes, Jose Fernandes E., Fraedrich, Gustav, Gupta, Ajay, Jawien, Arkadiusz, Jezovnik, Mateja K., Kakkos, Stavros K., Knoflach, Michael, Lal, Brajesh K., Lanza, Gaetano, Liapis, Christos D., Loftus, Ian M., Mansilha, Armando, and Millon, Antoine

Abstract

Background: The optimal antithrombotic (antiplatelet or anticoagulant) treatment of patients undergoing extracranial carotid artery interventions is a subject of debate. The aim of this multidisciplinary document was to critically review the recommendations of current guidelines, taking into consideration the results of recendy published studies. Methods:The various antithrombotic strategies reported were evaluated for asymptomatic and symptomatic patients undergoing extracranial carotid artery interventions (endarterectomy, transfemoral carotid artery stenting [CAS] or transcarotid artery revascularization [TCAR]). Based on a critical review, a series of recommendations were formulated by an international expert panel. Results: For asymptomatic patients, we recommend low-dose aspirin (75-100 ing/day) or dopidogrel (75 mg/day) with the primary goal to reduce the risk of myocardial infarction and cardiovascular event rates rather than to reduce the risk of stroke. For symptomatic patients, we recommend dual antiplatelet treatment (DAFT) initiated within 24 h of the index event to reduce the risk of recurrent events. We suggest that following transfemoral CAS or TCAR, patients continue DAFT for 1 month after which a single antiplatelet agent is used. High level of evidence to support anticoagulant treatment for patients with carotid artery disease is lacking. Condusions: The antithrombotic treatment offered to carotid patients should be individualized, taking into account the presence of symptoms, the type of intervention and the goal of the treatment. The duration and type of DAFr (ticagrelor instead of dopidogrel) should be evaluated in future trials. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

37. The Association of Arterial Stiffness With Significant Carotid Atherosclerosis and Carotid Plaque Vulnerability.

Author

Kadoglou, Nikolaos P.E., Moulakakis, Konstantinos G., Mantas, George, Kakisis, John D., Mylonas, Spyridon N, Valsami, Georgia, and Liapis, Christos D

Subjects
LIPID analysis, CAROTID artery surgery, BIOMARKERS, BIOCHEMISTRY, STATINS (Cardiovascular agents), C-reactive protein, CAROTID artery diseases, CAROTID artery stenosis, MULTIVARIATE analysis, CELL receptors, ARTERIAL diseases, DISEASE susceptibility, DESCRIPTIVE statistics, LONGITUDINAL method, COMORBIDITY, DISEASE risk factors
Abstract

Arterial stiffness and its valid index, the cardio-ankle vascular index (CAVI), have emerged as predictors of adverse cardiovascular outcomes. We investigated the relationship of the CAVI with significant carotid stenosis (> 50%) and the related cerebrovascular symptoms or carotid plaque echogenicity, assessed by ultrasound gray-scale median (GSM) score, at baseline and after carotid artery stenting (CAS). We prospectively enrolled 113 patients with carotid stenosis (70-99% for asymptomatic and > 50% for symptomatic participants) eligible for CAS. Age- and sex-matched individuals (n = 38) served as controls (CON). Clinical data, CAVI, and biochemical profile were obtained at baseline. Clinical assessment and CAVI measurement were performed 6 months after CAS. Compared with the CON group, the CAS group had a higher incidence of co-morbidities (diabetes, hypertension, and hyperlipidemia), higher CAVI values (9.94 ± 2.14 vs 7.85 ±.97 m/sec, P <.001), but a better lipid profile due to increased prescription of statins. The symptomatic CAS subgroup showed higher CAVI (P <.001), high-sensitivity C-reactive protein (P =.048), and osteoprotegerin (P =.002) levels than the asymptomatic one. In multivariate analysis, CAVI at baseline was independently associated with the presence of significant carotid atherosclerosis (β =.695, P <.001), cerebrovascular events (β =.474, P <.001), and GSM score (β = −.275, P =.042). Raised CAVI values were independently associated with significant carotid stenosis and plaque vulnerability. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

38. Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease.

Author

Paraskevas, Kosmas I., Gloviczki, Peter, Antignani, Pier Luigi, Comerota, Anthony J., Dardik, Alan, Davies, Alun H., Eckstein, Hans-Henning, Faggioli, Gianluca, Fernandes e Fernandes, Jose, Fraedrich, Gustav, Geroulakos, George, Golledge, Jonathan, Gupta, Ajay, Gurevich, Victor S., Jawien, Arkadiusz, Jezovnik, Mateja K., Kakkos, Stavros K., Knoflach, Michael, Lanza, Gaetano, and Liapis, Christos D.

Abstract

International guidelines strongly recommend statins alone or in combination with other lipid-lowering agents to lower low-density lipoprotein cholesterol (LDL-C) levels for patients with asymptomatic/symptomatic carotid stenosis (AsxCS/SCS). Lowering LDL-C levels is associated with significant reductions in transient ischemic attack, stroke, cardiovascular (CV) event and death rates. The aim of this multi-disciplinary overview is to summarize the benefits and risks associated with lowering LDL-C with statins or non-statin medications for Asx/SCS patients. The cerebrovascular and CV beneficial effects associated with statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and other non-statin lipid-lowering agents (e.g. fibrates, ezetimibe) are reviewed. The use of statins and PCSK9 inhibitors is associated with several beneficial effects for Asx/SCS patients, including carotid plaque stabilization and reduction of stroke rates. Ezetimibe and fibrates are associated with smaller reductions in stroke rates. The side-effects resulting from statin and PCSK9 inhibitor use are also highlighted. The benefits associated with lowering LDL-C with statins or non-statin lipid lowering agents (e.g. PCSK9 inhibitors) outweigh the risks and potential side-effects. Irrespective of their LDL-C levels, all Asx/SCS patients should receive high-dose statin treatment±ezetimibe or PCSK9 inhibitors for reduction not only of LDL-C levels, but also of stroke, cardiovascular mortality and coronary event rates. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results